Literature DB >> 29601842

Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.

Sumit Isharwal1, Hongying Huang2, Gouri Nanjangud3, François Audenet1, Ying-Bei Chen2, Anuradha Gopalan2, Samson W Fine2, Satish K Tickoo2, Byron H Lee1, Gopa Iyer4, Kalyani Chadalavada3, Jonathan E Rosenberg4, Dean F Bajorin4, Harry W Herr1, S Machele Donat1, Guido Dalbagni1, Bernard H Bochner1, David B Solit4, Victor E Reuter2, Hikmat A Al-Ahmadie5.   

Abstract

Micropapillary urothelial carcinoma (MPUC) is a rare but an aggressive variant of urothelial carcinoma. MPUC has been shown to commonly exhibit ERBB2 amplification and HER2 protein overexpression, but the frequency and distribution of these findings within micropapillary (MP) and not otherwise specified (NOS) components of tumors with mixed histology have not been addressed. Therefore, we evaluated ERBB2 amplification and HER2 expression in 43 MPUC cases by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Of the 35 tumors containing both MP and NOS components, ERBB2 amplification was present in both the MP and NOS components of 12 tumors (34.3%), in only the MP component of 11 tumors (31.4%), and exclusively in the NOS component of 4 tumors (11.4%). HER2 protein overexpression was significantly more commonly present in the MP component compared to the NOS component within the same tumor (68.6% versus 34.3%, P = .012). Overall, there was a moderately positive correlation between HER2 protein expression and ERBB2 amplification in both MP (ρ = 0.59, P < .001) and NOS (ρ = 0.70, P < .001) components. All MP/NOS areas with IHC score 3+ and none of MP/NOS areas with IHC score 0 were associated with ERBB2 amplification. We conclude that ERBB2 amplification and HER2 overexpression are preferentially but not exclusively identified in the MP component compared to the NOS component within the same tumor. Our findings identify the presence of intratumoral heterogeneity of ERBB2 amplification and HER2 expression in MPUC and provide grounds for further investigation into the mechanisms underlying the development of MPUC.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fluorescence in situ hybridization; Human epidermal growth factor receptor-2 (HER2, ERBB2); Immunohistochemistry; Intratumoral heterogeneity; Micropapillary urothelial carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29601842      PMCID: PMC6019182          DOI: 10.1016/j.humpath.2018.03.015

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  30 in total

1.  HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization.

Authors:  Christina B Ching; Mahul B Amin; Raymond R Tubbs; Paul Elson; Eric Platt; Robert Dreicer; Amr Fergany; Donna E Hansel
Journal:  Mod Pathol       Date:  2011-04-22       Impact factor: 7.842

Review 2.  HER2 testing in gastric and gastroesophageal adenocarcinomas.

Authors:  Efsevia Vakiani
Journal:  Adv Anat Pathol       Date:  2015-05       Impact factor: 3.875

3.  HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

Authors:  Pamela L Kunz; Amirkaveh Mojtahed; George A Fisher; James M Ford; Daniel T Chang; Raymond R Balise; Charles D Bangs; Athena M Cherry; Reetesh K Pai
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-01

4.  Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

Authors:  Achim Fleischmann; Diana Rotzer; Roland Seiler; Urs E Studer; George N Thalmann
Journal:  Eur Urol       Date:  2011-05-25       Impact factor: 20.096

5.  Micropapillary bladder carcinoma: a clinicopathological study of 20 cases.

Authors:  S L Johansson; G Borghede; S Holmäng
Journal:  J Urol       Date:  1999-06       Impact factor: 7.450

6.  Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.

Authors:  Joshua J Meeks; Jennifer M Taylor; Kazuhito Matsushita; Harry W Herr; S Machele Donat; Bernard H Bochner; Guido Dalbagni
Journal:  BJU Int       Date:  2013-02-05       Impact factor: 5.588

7.  Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.

Authors:  Sara Simonetti; Rosa Russo; Giuseppe Ciancia; Vincenzo Altieri; Gaetano De Rosa; Luigi Insabato
Journal:  Int J Surg Pathol       Date:  2009-06       Impact factor: 1.271

8.  Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.

Authors:  Ashish M Kamat; Colin P N Dinney; Jason R Gee; H Barton Grossman; Arlene O Siefker-Radtke; Pheroze Tamboli; Michelle A Detry; Tracy L Robinson; Louis L Pisters
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

9.  Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.

Authors:  J Tschui; E Vassella; N Bandi; U Baumgartner; V Genitsch; D Rotzer; R Seiler; G N Thalmann; A Fleischmann
Journal:  Virchows Arch       Date:  2015-03-26       Impact factor: 4.064

10.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962

View more
  6 in total

Review 1.  Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants.

Authors:  Hikmat Al-Ahmadie; Gopa Iyer
Journal:  Surg Pathol Clin       Date:  2018-10-17

2.  Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas.

Authors:  Simone Bertz; Armin Ensser; Robert Stoehr; Markus Eckstein; Hendrik Apel; Doris Mayr; Maike Buettner-Herold; Nadine Therese Gaisa; Eva Compérat; Bernd Wullich; Arndt Hartmann; Antje Knöll
Journal:  Mod Pathol       Date:  2020-02-11       Impact factor: 7.842

Review 3.  Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma.

Authors:  Elisa De Lorenzis; Giancarlo Albo; Fabrizio Longo; Carolina Bebi; Luca Boeri; Emanuele Montanari
Journal:  Genes (Basel)       Date:  2021-02-25       Impact factor: 4.096

Review 4.  [Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference].

Authors:  Oliver Hommerding; Yves Allory; Pedram Argani; Tarek A Bismar; Lukas Bubendorf; Sofía Canete-Portillo; Alcides Chaux; Ying-Bei Chen; Liang Cheng; Antonio L Cubilla; Lars Egevad; Anthony J Gill; David J Grignon; Arndt Hartmann; Ondrej Hes; Muhammad T Idrees; Chia-Sui Kao; Margaret A Knowles; Leendert H J Looijenga; Tamara L Lotan; Colin C Pritchard; Mark A Rubin; Scott A Tomlins; Theodorus H Van der Kwast; Elsa F Velazquez; Joshua I Warrick; Sean R Williamson; Glen Kristiansen
Journal:  Pathologe       Date:  2021-01-04       Impact factor: 1.011

Review 5.  Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.

Authors:  Joshua J Meeks; Hikmat Al-Ahmadie; Bishoy M Faltas; John A Taylor; Thomas W Flaig; David J DeGraff; Emil Christensen; Benjamin L Woolbright; David J McConkey; Lars Dyrskjøt
Journal:  Nat Rev Urol       Date:  2020-03-31       Impact factor: 14.432

Review 6.  Molecular Pathology of Urothelial Carcinoma.

Authors:  Hikmat Al-Ahmadie; George J Netto
Journal:  Surg Pathol Clin       Date:  2021-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.